Eli lilly and company(5조pt) new

Eli Lilly and company : Drug Development Strategy 5 조 류민웅 , 강태영

CONTENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

1. THE PHARMACEUTICAL INDUSTRY BUSINESS ,[object Object],[object Object]

[object Object],[object Object],( 표 . 처방약 세계매출 상위 20 개 품목 , 1994) 1. THE PHARMACEUTICAL INDUSTRY BUSINESS

1. THE PHARMACEUTICAL INDUSTRY BUSINESS ( 표 . 제약산업 상위 20 개 회사 ,1994) ,[object Object]

[object Object],[object Object],[object Object],< 주요 제품 판매현황 > 2. ELI LILLY AND COMPANY < 재무현황 (1993~1994)> ,[object Object],[object Object],CRISIS ,[object Object],[object Object],[object Object]

Hit to Lead Process : 6.5 년 ,[object Object],[object Object],[object Object],cf. US FDA3 단계임상실험 1 단계 : 임상 안전 테스트 2 단계 : 약의 효용성 평가 3 단계 : 장기복용에 대한 부작용 테스트 ,[object Object],[object Object],[object Object],[object Object],3. NEW DRUG DEVELOPMENT PROCESS Target Discovery Assay Development Lead Discovery Preclinical study Phase 1,2,3

<Ex. 신약 Pipeline> 3. NEW DRUG DEVELOPMENT PROCESS Discovery 2012 기능성 소화불량 DA-6773 2012 당뇨 DA-12229 2009 위염 DA-6034 2011 아토피성 피부염 DA-9102 2011 천식 DA-9201 2013 당뇨 PAM-1616 출시 예정 III II I Pre-clinical 적응증 Code name 2010 기능성 소화불량 DA-9701

Screening Lead Compounds Evaluation Clinic Market New Drug Natural Products Libraries Combinatorial Chemistry Libraries Chemical Libraries Functional Genomics Target ID Proteomics SNPs Genomics ensemble 3. NEW DRUG DEVELOPMENT PROCESS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],3. NEW DRUG DEVELOPMENT PROCESS

[object Object],4. INNOVATION IN THE DRUG DEVELOPMENT ,[object Object],[object Object],[object Object],Neurotransmitters released from one nerve cell are recognized by certain receptors located on the surface of another nerve cell, which, in turn, may respond appropriately Receptor specific for other types of transmitters Receptor specific for transmitter s | shown Hmolecular "key" fits the molecular Pock") Neurotransmitter (e.g., serotonin) Nerve cell (transmitting message) `

4. INNOVATION IN THE DRUG DEVELOPMENT ,[object Object],[object Object],[object Object],[object Object]

4. INNOVATION IN THE DRUG DEVELOPMENT ,[object Object],< 조합화학의 원칙 > 고전적입 합성법 조합화학 A + B = AB A1 A2 A3 . . An B1 B2 B3 . . Bn = An-1 Bn-1 ,[object Object],[object Object],[object Object],[object Object],[object Object],“ 나무의 잎사귀를 검사하는 것보다 가지를 검사하는 방법”

5. CONCLUSION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Eli lilly and company(5조pt) new

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Ähnlich wie Eli lilly and company(5조pt) new

Ähnlich wie Eli lilly and company(5조pt) new (20)

Eli lilly and company(5조pt) new